JP2013508315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508315A5 JP2013508315A5 JP2012534543A JP2012534543A JP2013508315A5 JP 2013508315 A5 JP2013508315 A5 JP 2013508315A5 JP 2012534543 A JP2012534543 A JP 2012534543A JP 2012534543 A JP2012534543 A JP 2012534543A JP 2013508315 A5 JP2013508315 A5 JP 2013508315A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- external
- pharmaceutical composition
- nacl
- internal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- 230000000065 osmolyte Effects 0.000 claims 4
- 239000008363 phosphate buffer Substances 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 claims 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 claims 1
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200901150A DK177529B1 (en) | 2009-10-23 | 2009-10-23 | Liposomes with improved storage stability |
| DKPA200901150 | 2009-10-23 | ||
| PCT/DK2010/050283 WO2011047689A2 (en) | 2009-10-23 | 2010-10-25 | Liposomes with improved storage stability |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508315A JP2013508315A (ja) | 2013-03-07 |
| JP2013508315A5 true JP2013508315A5 (enExample) | 2013-04-18 |
| JP5778160B2 JP5778160B2 (ja) | 2015-09-16 |
Family
ID=43533079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534543A Expired - Fee Related JP5778160B2 (ja) | 2009-10-23 | 2010-10-25 | ｓＰＬＡ２加水分解性リポソームを含む医薬組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9820941B2 (enExample) |
| EP (1) | EP2490671B1 (enExample) |
| JP (1) | JP5778160B2 (enExample) |
| CN (1) | CN102639114B (enExample) |
| AU (1) | AU2010310240B2 (enExample) |
| CA (1) | CA2772973C (enExample) |
| CY (1) | CY1115139T1 (enExample) |
| DK (2) | DK177529B1 (enExample) |
| ES (1) | ES2465565T3 (enExample) |
| HR (1) | HRP20140413T1 (enExample) |
| PL (1) | PL2490671T3 (enExample) |
| PT (1) | PT2490671E (enExample) |
| RS (1) | RS53321B (enExample) |
| SI (1) | SI2490671T1 (enExample) |
| SM (1) | SMT201400065B (enExample) |
| WO (1) | WO2011047689A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| EP2394640A1 (en) * | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| WO2015166987A1 (ja) * | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| WO2015166986A1 (ja) | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| JP6263609B2 (ja) * | 2014-04-30 | 2018-01-17 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| EP3291797B1 (en) * | 2015-05-04 | 2020-09-02 | Versantis AG | Method for preparing transmembrane ph-gradient vesicles |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2019200325A1 (en) * | 2018-01-31 | 2019-08-15 | Liplasome Pharma Aps | Methods for treating cancer and predicting drug responsiveness in cancer patients |
| CN110496103B (zh) * | 2018-05-18 | 2022-05-10 | 上海维洱生物医药科技有限公司 | 一种多西他赛棕榈酸酯脂质体及其制备方法 |
| JP7364561B2 (ja) | 2018-06-20 | 2023-10-18 | 富士フイルム株式会社 | ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| DE68901733T2 (de) | 1988-03-04 | 1993-03-25 | Takeda Chemical Industries Ltd | Liposom-zusammensetzung. |
| JP2931981B2 (ja) * | 1988-03-04 | 1999-08-09 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
| FI895340A7 (fi) * | 1988-11-14 | 1990-05-15 | Bristol Myers Squibb Co | Hypertoninen cisplatin-liuos |
| JPH05194192A (ja) * | 1991-08-21 | 1993-08-03 | Shionogi & Co Ltd | 分散性の改善された温度感受性ｍｌｖ型リポソ−ム |
| JPH069374A (ja) * | 1992-04-07 | 1994-01-18 | Banyu Pharmaceut Co Ltd | リポソ−ム製剤およびその製造法 |
| WO1996010585A1 (en) | 1994-09-30 | 1996-04-11 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| PT929293E (pt) * | 1996-08-23 | 2004-03-31 | Sequus Pharm Inc | Lipossomas contendo um composto de cisplatina |
| FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| JP2003522193A (ja) | 2000-02-10 | 2003-07-22 | リプラサム ファーマ アー／エス | ホスホリパーゼａ２で分解可能な脂質誘導体を含有する脂質をベースとした薬物送達系、および治療におけるその使用 |
| DK1272161T3 (da) | 2000-04-12 | 2008-05-19 | Liplasome Pharma As | Lipid-baserede system til afgivelse af lægemidler mod parasitiske infektioner |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| ES2387886T3 (es) | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
| US20040022842A1 (en) | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
| EP1643971A2 (en) | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| GB0312309D0 (en) * | 2003-05-29 | 2003-07-02 | Gaslini Children S Hospital G | Targeted liposome |
| CA2578921A1 (en) | 2004-08-31 | 2006-03-09 | Astellas Pharma Inc. | Intracellular drug delivery improving liposome |
| DE602005012155D1 (de) | 2004-11-03 | 2009-02-12 | Liplasome Pharma As | Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendung |
| US20070014845A1 (en) * | 2005-07-01 | 2007-01-18 | Yuanpeng Zhang | Liposomal delivery vehicle for hydrophobic drugs |
| CN101040853B (zh) * | 2006-03-22 | 2010-05-12 | 上海医药工业研究院 | 一种草乌甲素多泡脂质体及其制备方法 |
| CA2647779A1 (en) | 2006-03-23 | 2007-09-27 | Liplasome Pharma A/S | Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis |
| BRPI0714386A2 (pt) | 2006-07-14 | 2012-12-25 | Fmc Biopolymer As | hidrogel, conta, mÉtodos para produzir um hidrogel ou uma conta, para implantar uma conta ou dispositivo mÉdico implantÁvel e cÉlulas em um paciente, para bloquear vasos sanguÍneos, e para formar um hidrogel, dispositivo mÉdico implantÁvel, formulaÇço de liberaÇço de droga, agente de contraste ou material radioopaco, e, composiÇço terapÊutica embàlica |
| CN100563646C (zh) * | 2007-07-13 | 2009-12-02 | 陈祥峰 | 一种奥沙利铂脂质体葡萄糖制剂的制备方法 |
| EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
-
2009
- 2009-10-23 DK DKPA200901150A patent/DK177529B1/en not_active IP Right Cessation
-
2010
- 2010-10-25 PL PL10772956T patent/PL2490671T3/pl unknown
- 2010-10-25 JP JP2012534543A patent/JP5778160B2/ja not_active Expired - Fee Related
- 2010-10-25 DK DK10772956.8T patent/DK2490671T3/da active
- 2010-10-25 AU AU2010310240A patent/AU2010310240B2/en not_active Ceased
- 2010-10-25 EP EP10772956.8A patent/EP2490671B1/en active Active
- 2010-10-25 RS RS20140274A patent/RS53321B/sr unknown
- 2010-10-25 ES ES10772956.8T patent/ES2465565T3/es active Active
- 2010-10-25 HR HRP20140413AT patent/HRP20140413T1/hr unknown
- 2010-10-25 PT PT107729568T patent/PT2490671E/pt unknown
- 2010-10-25 US US13/503,614 patent/US9820941B2/en not_active Expired - Fee Related
- 2010-10-25 WO PCT/DK2010/050283 patent/WO2011047689A2/en not_active Ceased
- 2010-10-25 CA CA2772973A patent/CA2772973C/en active Active
- 2010-10-25 SI SI201030638T patent/SI2490671T1/sl unknown
- 2010-10-25 CN CN201080047402.7A patent/CN102639114B/zh not_active Expired - Fee Related
-
2014
- 2014-05-30 CY CY20141100387T patent/CY1115139T1/el unknown
- 2014-06-05 SM SM201400065T patent/SMT201400065B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508315A5 (enExample) | ||
| JP2014051497A5 (enExample) | ||
| JP2009531457A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2014520852A5 (enExample) | ||
| FI3223838T3 (fi) | Kultakiivin koostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| JP2012126742A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| NZ602685A (en) | Concentrated protein formulations and uses thereof | |
| JP2014507482A5 (enExample) | ||
| JP2010166916A5 (enExample) | ||
| BRPI0820308B8 (pt) | composição farmacêutica compreendendo oxi-hidróxido de ferro em alta carga, seus usos e seus processos de preparação, e comprimido | |
| PH12013500454A1 (en) | Substituted imidazopyridazines | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| MY198204A (en) | Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof | |
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| EA201270741A1 (ru) | Пероральные композиции и липофильные соли метилналтрексона | |
| CN102036649A8 (zh) | 精氨酸盐及其治疗口腔疾病的用途 | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| JP2013514797A5 (enExample) | ||
| MX2009011218A (es) | Microparticulas de acido nucleico para administracion pulmonar. | |
| HRP20140413T1 (hr) | Spla2 hidrolizirajuä†i liposomi s poboljšanim svojstvima pohranjivanja | |
| JP2014503593A5 (enExample) | ||
| JP2012529293A5 (enExample) | ||
| EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli |